Skip to main content

Table 3 Correlations (Spearman) between ETN concentration and disease activity

From: Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study

 

ETN concentration

MTX group

r (95% CI)

non-MTX group

r (95% CI)

ESR

-0.04 (-0.24 to 0.16)

-0.01 (-0.23 to 0.21)

CRP

-0.20 (-0.39 to -0.01)

-0.06 (-0.28 to 0.15)

PaGA

0.02 (-0.18 to 0.22)

-0.25 (-0.44 to -0.04)

PhGA

0.19 (-0.01 to 0.37)

-0.09 (-0.30 to 0.12)

JADAS10

0.13 (-0.07 to 0.32)

-0.22 (-0.42 to -0.01)

  1. No significant correlations after Sidak adjustment
  2. ETN etanercept, MTX methotrexate, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, PaGA Patient’s global assessment of wellbeing measured on a linear analogue scale (VAS), PhGA Physician’s global assessment of wellbeing measured on a VAS scale, JADAS10 10-joint Juvenile Arthritis Disease Activity Score
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096